Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,301–2,400 of 10,906
Drulovic, J. S., Ivanović, J., Martinović, V., Tamaš, O., Veselinovic, N., Ćujić, D., Gnjatović, M., Mesaroš, Š., & Pekmezovic, T. D. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103150 · Cited by 34
Sariol, C. A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina-Rodríguez, A., Cruz, L. A., Stone, E. T., Arana, T., Climent, C., Latoni, G., et al. (2021) · Viruses · doi:10.3390/v13101972 · Cited by 32
Myocarditis associated with COVID-19 and its vaccines - a systematic review
Rout, A., Suri, S. S., Vorla, M., & Kalra, D. K. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.10.004 · Cited by 42
Lin, S., Lau, L. H. S., Chanchlani, N., Kennedy, N. A., & Ng, S. C. (2022) · Gut · doi:10.1136/gutjnl-2021-326784 · Cited by 37
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Heitmann, J. S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S. M., Tegeler, C. M., Maringer, Y., Jaeger, S. U., Denk, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40758-0 · Cited by 38
Newman, P. A., Reid, L., Tepjan, S., Fantus, S., Allan, K., Nyoni, T., Guţă, A., & Williams, C. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266120 · Cited by 45
Tailoring Highly Branched Poly(β-amino ester)s for Efficient and Organ-Selective mRNA Delivery
Yong, H., Lin, L., Li, Z., Guo, R., Wang, C., Liu, S., & Zhou, D. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02440 · Cited by 38
Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.07.082 · Cited by 36
(2021) · doi:10.1101/2021.04.14.21255431 · Cited by 62
Evaluation of adverse effects with COVID-19 vaccination in Pakistan
Abbas, D. S., Abbas, B., Amir, S., & Wajahat, M. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.7.4522 · Cited by 38
Wang, X., Haeussler, K., Spellman, A., Phillips, L. E., Ramiller, A., Bausch-Jurken, M. T., Sharma, P., Krivelyova, A., Vats, S., & de Velde, N. V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204831 · Cited by 32
Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
Meng, H., Mao, J., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27590 · Cited by 36
Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines
Lin, D.-Y., Zeng, D., & Gilbert, P. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab226 · Cited by 34
Self-citationFighting coronaviruses with natural polyphenols
da Silva, A. P. G. (2021) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2021.102179 · Cited by 34
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 46
Rogers, J. H., Cox, S. N., Hughes, J. P., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.026 · Cited by 34
Antiplatelet drugs block platelet activation by VITT patient serum
Smith, C. W., Montague, S. J., Kardeby, C., Di, Y., Lowe, G., Lester, W., Watson, S. P., & Nicolson, P. L. R. (2021) · Blood · doi:10.1182/blood.2021012277 · Cited by 40
Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response
Mahmoud, S., Ganesan, S., Naik, S. V., Bissar, S., Zamel, I. A., Warren, K., Zaher, W. A., & Khan, G. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00733-21 · Cited by 33
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 31
Opportunities and Challenges for mRNA Delivery Nanoplatforms
Zhang, Y., Hu, Y., Tian, H., & Chen, X. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03898 · Cited by 35
Iguacel, I., Maldonado, A. L., Ruíz-Cabello, A. L., Samatán, E., Alarcón, J., Orte, M. Á., Mateos, S. S., & Martínez‐Jarreta, B. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.739003 · Cited by 33
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 39
Kartnig, F., Mrak, D., Simader, E., Tobudic, S., Radner, H., Mandl, P., Göschl, L., Hommer, N., Mayer, M., Hofer, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222682 · Cited by 31
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 39
Borisova, N. I., Kotov, I. A., Kolesnikov, A. A., Kaptelova, V. V., Speranskaya, A. S., Kondrasheva, L. Y., Tivanova, E. V., Khafizov, K., & Акимкин, В. Г. (2021) · Problems of Virology · doi:10.36233/0507-4088-72 · Cited by 33
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Andreana, I., Repellin, M., Carton, F., Kryza, D., Briançon, S., Chazaud, B., Mounier, R., Arpicco, S., Malatesta, M., Stella, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020278 · Cited by 40
A new dawn for monoclonal antibodies against antimicrobial resistant bacteria
Troisi, M., Marini, E., Abbiento, V., Stazzoni, S., Andreano, E., & Rappuoli, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1080059 · Cited by 41
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Lyke, K. E., Atmar, R. L., Islas, C. P. D., Posavad, C. M., Deming, M. E., Branche, A. R., Johnston, C., Sahly, H. M. E., Edupuganti, S., Mulligan, M. J., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00693-z · Cited by 34
Self-citationCassaniti, I., Bergami, F., Percivalle, E., Gabanti, E., Sammartino, J. C., Ferrari, A., Adzasehoun, K. M. G., Zavaglio, F., Zelini, P., Comolli, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.016 · Cited by 38
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 36
Canetti, M., Barda, N., Gilboa, M., Indenbaum, V., Mandelboim, M., Gonen, T., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Doolman, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35480-2 · Cited by 37
The infinite possibilities of RNA therapeutics
Lara, E. C. M., Ni, M., Agathos, S. N., & Gonzales-Zubiate, F. A. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab063 · Cited by 36
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 42
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
Fuentes, J. D. B., Mohamed, K. M., Aguilar, A. D. L., García, C. J., Guevara‐Hoyer, K., Fernández‐Arquero, M., de la Peña, M. A. R., García-Bravo, L., Ortega, A. F. J., Navarro, P. F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975980 · Cited by 34
Single-Molecule FRET Imaging of Virus Spike–Host Interactions
Lu, M. (2021) · Viruses · doi:10.3390/v13020332 · Cited by 40
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
Underwood, E., Dunkle, L. M., Madhi, S. A., Gay, C. L., Heath, P. T., Kotloff, K. L., Smith, K., Chau, G., Galbiati, S., McGarry, A., et al. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2218913 · Cited by 36
Self-citationEvolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
Antunes, R. D. S., Fajardo-Rosas, V., Yu, E. D., Gálvez, R. I., Abawi, A., Escarrega, E. A., Martínez-Pérez, A., Johansson, E., Goodwin, B., Frazier, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115907 · Cited by 41
Darney, B. G., Boniface, E. R., van Lamsweerde, A., Han, L. L., Matteson, K. A., Cameron, S. T., Male, V. H., Acuna, J. M., Benhar, E., Pearson, J. T., et al. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17471 · Cited by 35
Ma, X., Liu, S., Fan, B., Jin, D., Miao, L., Liu, L., Du, S., & Lin, J. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102485 · Cited by 39
Wang, J., Zhang, Q., Ai, J., Liu, D., Liu, C., Xiang, H., Gu, Y., Guo, Y., Lv, J., Huang, Y., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10332-9 · Cited by 33
Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review
Temiz, S. A., Abdelmaksoud, A., Wollina, U., Kutlu, Ö., Dursun, R., Patil, A. D., Lotti, T., Goldust, M., & Vestita, M. G. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14613 · Cited by 34
Perrier, Q., Lupo, J., Gerster, T., Augier, C., Falque, L., Rostaing, L. P. E., Pelletier, L., Bedouch, P., Blanc, M., Saint‐Raymond, C., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.065 · Cited by 36
Martin, W. R., & Cheng, F. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1894986 · Cited by 36
Shaw, C. A., Mithani, R., Kapoor, A., Dhar, R., Wilson, L., Asmar, L. E., Ghamloush, S. S., Schaefers, K., August, A., Stoszek, S., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae035 · Cited by 39
Kircheis, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910791 · Cited by 36
Machine learning techniques for lipid nanoparticle formulation
Li, H., Zhao, Y., & Xu, C. (2025) · Nano Convergence · doi:10.1186/s40580-025-00502-4 · Cited by 43
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 40
Halfmann, P., Loeffler, K., Duffy, A., Kuroda, M., Yang, J. E., Wright, E., Kawaoka, Y., & Kane, R. S. (2024) · Nature Communications · doi:10.1038/s41467-024-45495-6 · Cited by 33
Li, X., Gao, L., Tong, X., Chan, V. K. Y., Chui, C. S. L., Lai, F. T. T., Wong, C. K. H., Wan, E. Y. F., Chan, E. W., Lau, K. K., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102830 · Cited by 36
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 40
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 34
Gilham, D., Smith, A. L., Fu, L., Moore, D. Y., Muralidharan, A., Reid, S. P., Stotz, S. C., Johansson, J. O., Sweeney, M., Wong, N. C. W., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040437 · Cited by 32
Maiese, A., Baronti, A., Manetti, A. C., Paolo, M. D., Turillazzi, E., Frati, P., & Fineschi, V. (2022) · Vaccines · doi:10.3390/vaccines10020308 · Cited by 37
Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 38
Shim, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147578 · Cited by 35
Sohi, A. N., Kiani, J., Arefian, E., Khosrojerdi, A., Fekrirad, Z., Ghaemi, S., Zim, M. K., Jalili, A., Bostanshirin, N., & Soleimani, M. (2021) · Vaccines · doi:10.3390/vaccines9091007 · Cited by 32
Shimizu, K., Iyoda, T., Sanpei, A., Nakazato, H., Okada, M., Ueda, S., Kato-Murayama, M., Murayama, K., Shirouzu, M., Harada, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02885-6 · Cited by 36
Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo
Wu, S., Su, K., Yan, X., Shi, L., Lin, L., Ren, E., Zhou, J., Zhang, C., Song, Y., & Liu, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.028 · Cited by 35
The time to offer treatments for COVID-19
Ngo, B., Marik, P. E., Kory, P. D., Shapiro, L., Thomadsen, R., Iglesias, J. I., Ditmore, S., Rendell, M., Varón, J., Dubé, M. P., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1901883 · Cited by 32
Nassir, C. M. N. C. M., Hashim, S., Wong, K. K., Halim, S. A., Idris, N. S., Jayabalan, N., Guo, D., & Mustapha, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02457-z · Cited by 37
Olfactory immune response to SARS-CoV-2
Wellford, S. A., & Moseman, E. A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01119-5 · Cited by 37
Subacute cutaneous lupus erythematosus flare triggered by COVID ‐19 vaccine
Joseph, A. K., & Chong, B. F. (2021) · Dermatologic Therapy · doi:10.1111/dth.15114 · Cited by 33
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Liu, H.-L., Wei, P., Zhang, Q.-Q., et al. (2021) · bioRxiv · doi:10.1101/2021.02.16.431305 · Cited by 80
A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects
Lentzen, M.-P., Huebenthal, V., Kaiser, R., Kreppel, M., Zöeller, J. E., & Zirk, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.052 · Cited by 39
Boros, L. G., Kyriakopoulos, A. M., Brogna, C., Piscopo, M., McCullough, P. A., & Seneff, S. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1218 · Cited by 48
Acute Arterial Ischemic Stroke Following COVID-19 Vaccination: A Systematic Review and Meta-analysis
Stefanou, M., Palaiodimou, L., de Sousa, D. A., Theodorou, A., Bakola, E., Katsaros, D. E., Halvatsiotis, P., Tzavellas, E., Naska, A., Coutinho, J. M., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200996 · Cited by 39
Lian, Z., Zheng, L., Liu, S., Zhang, J., Zhou, J. J., Wu, J., Ouyang, S., Li, J., & Yang, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05367 · Cited by 37
mRNA vaccines induce rapid antibody responses in mice
Gebre, M. S., Rauch, S., Roth, N., Gergen, J., Yu, J., Liu, X., Cole, A. C., Mueller, S. O., Petsch, B., & Barouch, D. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00511-y · Cited by 34
Tang, J., Rakshit, M., Chua, H. M., Darwitan, A., Nguyen, L. T. H., Muktabar, A., Venkatraman, S. S., & Ng, K. W. (2021) · Nanotechnology · doi:10.1088/1361-6528/ac2810 · Cited by 32
A review of COVID-19 vaccination and the reported cardiac manifestations
Ho, J. S. Y., Sia, C., Ngiam, J. N., Loh, P. H., Chew, N., Kong, W. K. F., & Poh, K. K. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021210 · Cited by 37
Haley, R. M., Padilla, M. S., El-Mayta, R. D., Joseph, R. A., Weber, J. A., Figueroa‐Espada, C. G., Mukalel, A. J., Ricciardi, A. S., Palanki, R., Geisler, H. C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16617 · Cited by 42
Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level
Chouchana, L., Blet, A., Al-Khalaf, M. H., Kafil, T. S., Nair, G. M., Robblee, J. A., Drici, M., Valnet‐Rabier, M., Micallef, J., Salvo, F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2499 · Cited by 36
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 33
Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
Otero‐Romero, S., Ascherio, A., & Lebrun‐Frénay, C. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000929 · Cited by 33
Meyer, M., Wang, Y., Edwards, D. K., Smith, G. R., Rubenstein, A. B., Ramanathan, P., Mire, C. E., Pietzsch, C. A., Chen, X., Ge, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148036 · Cited by 43
Self-citationAbe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., et al. (2021) · doi:10.1101/2021.08.06.21261721 · Cited by 32
“In healthy individuals, the first dose of vaccine does induce good protection against severe disease (although weaker than the two-dose regimen) and symptomatic infection associated with different variants [31, 32], despite lower neutralization levels than elicited by the full 2-doses.”
BackgroundSARS-CoV-2 Vaccination During Pregnancy: A Complex Decision
Wang, E. W., Parchem, J. G., Atmar, R. L., & Clark, E. H. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab180 · Cited by 33
Jacob-Dolan, C., Feldman, J. E., McMahan, K., Yu, J., Zahn, R. C., Wegmann, F., Schuitemaker, H., Schmidt, A. G., & Barouch, D. H. (2021) · Journal of Virology · doi:10.1128/jvi.00117-21 · Cited by 34
Drury, R. E., Camara, S., Chelysheva, I., Bibi, S., Sanders, K. A., Felle, S., Emary, K. R. W., Phillips, D. J., Voysey, M., Ferreira, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47463-6 · Cited by 35
Sprengholz, P., Eitze, S., Korn, L., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.015 · Cited by 32
Shenyu, W., Duan, X., Chen, B., Xuan, D., Wang, Z., Hangjie, Z., Zheng, Q., Liang, Z., Chuanfu, Y., Juan, Y., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.021 · Cited by 34
COVID-19 vaccination immune paresis in heart and lung transplantation
Aslam, S., Danziger‐Isakov, L. A., & Mehra, M. R. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.018 · Cited by 38
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia
Morawska, M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13722 · Cited by 32
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32
Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments
Garaizar, A., Díaz‐Oviedo, C. D., Zablowsky, N., Rissanen, S., Köbberling, J., Sun, J., Steiger, C., Steigemann, P., Mann, F. A., & Meier, K. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404555121 · Cited by 40
A Mini Review on SARS-COVID-19-2 Omicron Variant (B.1.1.529)
Ettaboina, S. K., Nakkala, K., & Laddha, K. S. (2021) · SciMedicine Journal · doi:10.28991/scimedj-2021-0304-10 · Cited by 33
Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
Presti, S. L., Elajami, T. K., Reyaldeen, R. M., Anthony, C. M., Imazio, M., & Klein, A. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021685 · Cited by 35
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 37
(2021) · doi:10.1101/2021.03.30.21254655 · Cited by 49
Nakatani, S., Mori, K., Morioka, F., et al. (2022) · CEN Case Reports · doi:10.1007/s13730-021-00677-9 · Cited by 32
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccinesPreprint
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.25.457692 · Cited by 32
Bajwa, H. M., Novak, F., Nilsson, A. C., Nielsen, C., Holm, D. K., Østergaard, K., Witt, A. H., Byg, K., Johansen, I. S., Mittl, K., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103729 · Cited by 33
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Chen, Q., Chang, Y., He, X., Ding, Y., Wang, R., Luo, R., Yuan, J., Chen, J., Zhong, G., Yang, H. Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14041 · Cited by 36
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Wolf, D. G., & Porat, S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac135 · Cited by 35
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.